New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Amgen Inc.

AMGN

Healthcare Drug Manufacturers General

Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024.

Revenue
+8.45%
EPS
+19.4%
Free cash flow
−14.0%
Total debt
−1.06%

Quarter to September 2026, against a year earlier

439.53 0.73 +0.17%
Market cap
$237.4B
P/E
25.2×
Fwd P/E FY26e
24.0×
Dividend yield
2.84%
F-score
7/9
ROIC
14.3%
Net debt / EBITDA
2.9×
Payout ratio
0.7×

Amgen Inc. (AMGN) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 16 added · 9 removed · 56 modified
P2I1A: 1 added · 38 removed · 17 modified
8-K Nov 3, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Oct 26, 2026 5.02 Departure or appointment of directors or officers Officer departure
10-Q Jun 30, 2026 P1I2: 13 added · 6 removed · 63 modified
P2I1A: 26 added · 9 removed · 24 modified
8-K Aug 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jul 29, 2026 1.05 Material cybersecurity incident Cybersecurity incident
8-K May 19, 2026 5.07 Submission of matters to a vote of security holders
8-K May 19, 2026 5.02 Departure or appointment of directors or officers
10-Q Mar 31, 2026 P1I2: 22 added · 33 removed · 53 modified
P2I1A: 61 added
8-K Apr 30, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 22, 2026 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
8-K Feb 17, 2026 1.01 Entry into a material definitive agreement; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 32 added · 28 removed · 84 modified
1A: 9 added · 9 removed · 99 modified
7: 30 added · 18 removed · 74 modified
8-K Feb 3, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 30, 2026 1.02 Termination of a material definitive agreement; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025 P1I2: 13 added · 17 removed · 58 modified
P2I1A: 41 removed · 12 modified
8-K Nov 4, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025 P1I2: 26 added · 9 removed · 50 modified
P2I1A: 43 added · 32 removed · 12 modified
8-K Aug 5, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025 P1I2: no comparison — the earlier filing's text is no longer kept
P2I1A: 58 added
8-K May 1, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024 1: no comparison — no earlier filing on file
1A: no comparison — no earlier filing on file
7: no comparison — no earlier filing on file
8-K Feb 4, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Oct 30, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 6, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 2, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 6, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.